According to Deutsche Presse-Agentur, the World Health Organization (WHO) inadvertently published a study on the drug “Remdeciver”, which is being produced by the American company “Gilead Sciences”, and the British newspaper “Financial Times” was the first to talk about the report, and the report stated that The drug did not improve the patient’s condition.
The share price of “Gilead” fell sharply against the background of the report, which led to a decline in the US market, as the broader Standard & Poor’s index of the New York Stock Exchange lost its gains during today’s trading session.
The company did not immediately respond to a request for comment, but said in a statement to the “Financial Times” that the study was not completed, as it was “canceled early due to the small number of participants, and its results should not be considered scientific.”
Gilead said that “trends in the data” still indicate potential benefits for patients treated early.
The study was conducted in China on 237 patients, of whom 158 underwent drug treatment.
Other studies are underway in the United States of America, and it is expected that these data will begin to be released within weeks.
